NeraCare formed a strategic partnership with SkylineDx, which includes an exclusive co-development and licensing agreement for Immunoprint, a proteomic test used to identify early-stage melanoma patients at high risk of relapse and death.
Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.
